Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BHR Pharma has recruited approximately 200 patients in a Phase 3 trial evaluating SyNAPSe as a treatment for progesterone for traumatic brain injury (TBI).
Subscribe to our email newsletter
The company expects to recruit around 1,200 patients with severe TBI (Glasgow Coma Scale scores of 4-8), who have sustained a closed-head trauma in SyNAPSe trial.
The results from previous US and China trials demonstrated 50% lower mortality in the progesterone-treated group as compared to placebo.
BHR CEO Tom MacAllister said the 200 subjects in the study include victims of automobile crashes, domestic abuse and other accidents that have left them permanently disabled.